What is known and objective: The purpose of this study was to evaluate the association between early β-blocker continuation and major inpatient events in patients hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
| WHAT IS K NOWN AND OBJEC TIVE
Chronic obstructive pulmonary disease (COPD) is characterized by aberrant and persistent inflammation, both local and systemic, leading to progressive decline in lung function.
1 Currently, COPD is included within the third leading cause of death in the United States and is projected to continue to increase.
2 Cardiovascular comorbidity is common in patients with COPD due to shared risk factors, such as smoking, age and genetic susceptibility. 3 Despite evidence demonstrating beneficial effects in COPD patients treated long-term with a β-blocker, many physicians avoid prescribing β-blockers in this patient population due to presumed bronchoconstrictive properties and a perceived clinically significant antagonism of β2 agonists. While hypoxaemia is known to elicit a hyperadrenergic state and exacerbate conditions like arrhythmias and ischaemic heart disease, there is evidence to support sympathetic activation in normoxic COPD patients. 5 Factors such as pulmonary stretch have been proposed to create an imbalance between sympathovagal balance, favouring an increase in resting sympathetic activity. 6 Given the overlap of cardiovascular symptoms and comorbidities in patients with COPD, and the hypothetical benefit of regulating an already overactive sympathetic system, β-blockers appear to be an ideal therapeutic option and may ameliorate adverse cardiovascular events. 5 β-blocker use in patients with COPD has been associated with lower mortality, but remains an underutilized therapy in the treatment paradigm. 7, 8 The cardioprotective effects of β-blockers are presumed to benefit the COPD population, similar to the benefits in cardiovascular disease (CVD) including hypertension, heart failure and ischaemic heart disease. 8 While mortality from acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is relatively low, factors that have been associated with worse outcomes include: troponin elevations, atrial fibrillation, ventricular arrhythmias and ischaemic heart disease.
9-11
Previous literature identifies a role for β-blockers in the management of COPD, but there is a paucity of evidence regarding utilization of this medication class during an acute exacerbation. An evaluation of the protective role of β-blockers on cardiovascular outcomes in patients hospitalized for AECOPD may lead to a paradigm shift to approach COPD from a true cardiopulmonary approach. The purpose of this study was to assess the association between early β-blocker utilization and major inpatient events in an AECOPD.
| ME THODS
This was a retrospective cohort study that evaluated patients admitted to a single, academic medical centre for an AECOPD from were assigned to the early β-blocker group if they were admitted for a primary diagnosis of AECOPD, and β-blocker therapy was ini- 
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The primary outcome was the association between early β- Continuous variables were expressed as means and standard deviations and analyzed using Wilcoxon rank-sum test. Categorical variables were represented as counts and percentages and analyzed using Chi-squared or Fisher's exact test where appropriate. Time-toevent data were reported using Kaplan-Meier curves. As previous evidence currently does not exist in regard to the impact of β-blockade in this acute time frame, power was calculated utilizing similar populations. Thus, the current study assumed 40% of patients not receiving early initiation (within 24 hours of admission) of β-blocker therapy would experience a major inpatient event. The event rate
was extrapolated from cardiothoracic surgery data where atrial fibrillation occurs in 25%-40% of patients. 13 Additionally, based on this previous evidence and the impact seen with β-blockade, an odds ratio of 3.9 was assumed. With 80% power and a two-sided 5% significance level, a total of 74 patients were needed to be adequately powered to detect a difference. All analyses were performed using SAS ® Version 9.4 for Windows.
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| RE SULTS
Study enrolment is outlined in Figure 1 . There were 170 patients who were admitted with a primary diagnosis of AECOPD. Baseline characteristics were similar between groups, except β-blocker use prior to admission and at discharge was more prevalent in the early β-blocker group (Table 1) . Metoprolol (n = 17; 94.4%) and carvedilol (n = 31; 96.9%) were the most commonly prescribed cardioselective and non-cardioselective β-blockers, respectively, prior to admission.
The prevalence of β-blocker use prior to hospital admission in the early β-blocker group was highest for hypertension (n = 28; 56%), followed by heart failure (n = 20; 40%), coronary artery disease (n = 15; 30%) and atrial fibrillation (n = 9; 18%). In the control group, the two patients who were prescribed β-blockers prior to hospital admission were on therapy for coronary artery disease (n = 1) and heart failure (n = 1).
Early β-blocker administration in patients admitted for AECOPD was associated with a lower incidence of major inpatient events compared with the control group (40% vs 80.5%; P < 0.001). Similarly, arrhythmias occurred less frequently in those patients receiving early β-blockers (30.9% vs 65.9%; P = 0.001). However, there was no difference in the incidence of MI (9.1% vs 14.6%; P = 0.54) or death (0 vs 0) between cohorts. Continuation of early β-blockade was associated with a decreased time to major inpatient events (P < 0.001) and arrhythmias (P < 0.001), but was not associated with a difference in time to MI between groups (P = 0.57; Figure 2 ). Of note, the incidence of atrial fibrillation was similar between the early β-blocker continuation (n = 4; 7.3%) and control patients (n = 3; 7.3%), while the incidence of supraventricular tachycardia was 10.9% (n = 6) and 41.5% (n = 17), respectively. Early β-blocker continuation was not associated with increased utilization of corticosteroids (P = 0.99) and bronchodilators, including the use of β2 agonists (P = 0.99), during the indexed AECOPD admission compared with the control group (Table 1) .
F I G U R E 1 Enrollment flow diagram
No differences in all-cause 30-day readmission rates (36% vs 27%; P = 0.32) and 30-day readmissions secondary to AECOPD (7% vs 20%; P = 0.12) were identified with receipt of early β-blockade. During hospitalization, β-blocker therapy was held for at least 24 hours in nine patients (16.4%) for bradycardia (n = 1) and hypotension (n = 8); however, none of these events resulted in permanent β-blocker discontinuation.
Metoprolol (n = 16; 94.1%) and carvedilol (n = 33; 97.1%) were the most commonly prescribed β-blockers at discharge. There were no between group differences in any of the remaining efficacy (Table 2) or safety (Table 3) outcomes. 
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| D ISCUSS I ON
To assess the impact of early β-blocker use in an AECOPD, this study evaluated major inpatient outcomes in patients receiving β-blockers within 24 hours of admission. Early β-blocker utilization in patients hospitalized for AECOPD was associated with a lower overall rate of major inpatient events. Given the overlap of COPD and CAD and the multiple shared risk factors for arrhythmias, patients in this study receiving β-blockers experienced significantly fewer arrhythmias. Cardiovascular complications, like arrhythmias, can induce or be a complication of AECOPD. 15 Though not statistically significant, ICU length of stay was greater in the early β-blocker cohort. However, this might be attributed to clinically relevant differences in Charlson Comorbidity Index and SOFA scores, representing a higher burden of comorbid illnesses and illness acuity in the early β-blocker group. Despite early utilization, β-blocker administration did not appear to be associated with a significantly higher rate of adverse pulmonary events, such as mechanical ventilation and bronchospasms. Even in patients with severe AECOPD, β-blockers were associated with lower rates of arrhythmias, without resulting in related adverse events.
The current study supports early β-blocker utilization in AECOPD, thereby favouring the cardiopulmonary model of COPD management. Terzano et al, 16 identified the increased prevalence of atrial fibrillation in AECOPD patients with reduced FEV 1 within the moderate airflow limitation category. Similarly, in a quazi-experimental study by Bhatt et al, 17 the PR interval was significantly longer and P wave dispersion was higher in patients with frequent acute exacerbations of COPD compared with those without. These under-recognized electrical modelling events and arrhythmias may precipitate and/or be a consequence of AECOPD. Precipitation, or presence of atrial fibrillation in patients hospitalized for AECOPD is considered one of the five strongest predictors of mortality and was validated as part of the DECAF (extended MRC Dyspnoea, eosinopenia, consolidation, acidemia and atrial fibrillation) score for predicting in-hospital mortality by Steer et al 18 While evidence is lacking in the AECOPD population, the ability for β-blockers to prevent atrial fibrillation has been documented in other disease states. 19 The current study adds to a growing body of evidence supporting the early administration of β-blockers to attenuate CV events secondary to the hypoxic and hyperadrenergic state of AECOPD. Together, this further supports the need to identify and reduce the incidence of arrhythmias early in an AECOPD with β-blocker therapy.
Though not statistically significant, hypotension occurred more frequently in AECOPD patients receiving early β-blocker initiation.
However, these events were not sustained and did not result in per- Utilizing β-blockers to attenuate the adverse impacts of atrial fibrillation in the setting of AECOPD could provide long-term mortality benefits. However, these results need to be validated with randomized, prospective trials. Similarly, the impact of early β-blocker utilization in a β-blocker naïve population experiencing AECOPD is an area of future research.
| WHAT IS NE W AND CON CLUS I ON S
Cardiovascular diseases play an important role in the pathogenesis and prognosis of AECOPD. 22 β-blocker therapy could result in a paradigm shift in managing COPD patients from a true cardiopulmonary approach. The current data suggest β-blocker continuation early in an AECOPD is associated with a reduced rate of cardiovascular events without a higher rate of adverse effects to compromise patient safety.
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